Sophiris Bio Inc. (NASDAQ:SPHS) a biopharmaceutical company developing treatments for urologic diseases on 19 may announced it has entered into a common stock purchase agreement with Aspire Capital Fund LLC an Illinois limited liability company (“Aspire Capital”). Sophiris Bio Inc. (NASDAQ:SPHS) weekly performance is -17.81%. On last trading day company shares ended up $2.40. Analysts mean target price for the company is $8.63. Sophiris Bio Inc. (NASDAQ:SPHS) distance from 50-day simple moving average (SMA50) is -25.17%.
NanoString Technologies, Inc., (NASDAQ:NSTG) on 3 June announced that it has entered into a collaboration with Celgene Corporation (NASDAQ:CELG) to develop a companion diagnostic assay using the nCounter®Analysis System to support the clinical validation of REVLIMID® for treatment of Diffuse Large B-Cell Lymphoma (DLBCL). NanoString Technologies Inc. (NASDAQ:NSTG) shares fell -8.06% in last trading session and ended the day on $15.29. NSTG gross Margin is 52.20% and its return on assets is -52.10%.NanoString Technologies Inc. (NASDAQ:NSTG) quarterly performance is -23.36%.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, on 2 June announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with advanced or metastatic solid tumors and an ongoing Phase 1b food effects study of Selinexor in patients with advanced sarcomas at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares moved down -5.05% in last trading session and was closed at $25.17, while trading in range of $25.05 – $26.74. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) year to date (YTD) performance is 9.82%.
Hyperion Therapeutics, Inc. (NASDAQ:HPTX) on 3 June announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Hyperion Therapeutics Inc. (NASDAQ:HPTX) ended the last trading day at $26.95. Company weekly volatility is calculated as 6.13% and price to cash ratio as 4.52.Hyperion Therapeutics Inc. (NASDAQ:HPTX) showed a negative weekly performance of -7.93%.
Receptos Inc. (NASDAQ:RCPT) Director Kristina Burow sold 153,698 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.74, for a total value of $4,570,978.52. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $396,523. Receptos Inc. (NASDAQ:RCPT) weekly performance is -12.63%. On last trading day company shares ended up $26.00. Analysts mean target price for the company is $59.00. Receptos Inc. (NASDAQ:RCPT) distance from 50-day simple moving average (SMA50) is -22.66%.
Leave a Reply